Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of June 2021. The report, dated June 14, 2021, incorporates by reference a press release (Exhibit 99.1) and is signed by Laure-Hélène Mercier, Chief Financial Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The document serves as a cover for a press release but does not include the text of that release. Consequently, there is no management commentary, guidance, outlook, risk disclosure, or description of unusual items within the provided content.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated June 14, 2021) for the actual content of the announcement.
- Verify the specific clinical or corporate event triggering this filing, as the cover sheet does not describe it.
- Check subsequent filings for any financial impact resulting from the event described in the press release.